Novo Nordisk A/S (NYSE:NVO) plans to limit initial sales of its obesity treatment Wegovy in China as the Danish drugmaker faces the challenge of balancing demand while ensuring global supply. China’s National Health Commission survey revealed over half of its 1.4 billion population is overweight or obese. Also Read: Novo Nordisk’s Older Generation Weight-Loss Drug Saxenda Associated With Decreased Bone Mass Density, Study Shows. Maziar Mike Doustdar, Novo Nordisk’s chief of international operations, stated the company aims to launch Wegovy in China soon, prioritizing continuous supply without affecting availability elsewhere. China’s health authorities recently approved Wegovy, offering a new weight loss option in a market where Novo Nordisk’s ...